Industry
Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 5:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 9:37 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:00 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 9:48 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 10:22 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.